Why fungal infections are getting harder to treat
Fungi are behind everything from athlete’s foot to life-threatening infections in hospital patients, and some are becoming resistant to the few drugs we have. This guide explains the two main growth forms of fungi, the fungi health agencies watch most closely, how antifungal resistance develops, and why treatment can fail.

1. Filamentous vs non-filamentous fungi
Fungi grow in two basic forms. Yeasts are single cells; molds are multicellular and grow as threads called hyphae. [11] Some fungi, such as Candida albicans, are dimorphic and can switch between the two. [11]
-
Yeasts (non-filamentous): Single cells that reproduce by budding off a smaller daughter cell. Sometimes the cells stay attached in short chains called pseudohyphae. [11] Examples: Candida albicans, Candida auris, Cryptococcus neoformans.
-
Molds (filamentous): Filaments called hyphae that can form a tangled network, the mycelium. [11] Molds live indoors and outdoors. [7] Aspergillus spreads through microscopic airborne spores. [8] Examples: Aspergillus fumigatus, Fusarium.
Where drug-resistant fungi show up
Most people meet fungi every day without getting sick. The risk is highest for people who are already very ill or have weakened immune systems. [7]
-
Hospital yeasts: Healthcare-associated fungal diseases such as candidemia and Candida auris infections are among the most severe. [7]
-
Airborne molds: Most people breathe in Aspergillus spores every day without getting sick, but people with weakened immune systems or lung disease are at higher risk. [8]
-
Skin and tissue: Fusarium causes superficial, locally invasive and disseminated infections. Severe disease mostly affects people with weakened immune systems. [13]
2. Priority fungi: The fungi health agencies watch most closely
In 2022 WHO published its first fungal priority pathogens list: 19 fungi grouped as critical, high or medium priority, mainly based on their public health impact and emerging antifungal resistance. [1]
-
Critical: Candida albicans, Aspergillus fumigatus, Candida auris, Cryptococcus neoformans [2]
-
High: Fusarium species, Candida tropicalis, Candida parapsilosis [2]
CDC’s 2026 report lists C. auris as an urgent threat and drug-resistant Candida as a serious threat, and keeps azole-resistant Aspergillus fumigatus on its watch list. [6]
Spotlight: Candida auris
-
A yeast that spreads in hospitals: C. auris (also called Candidozyma auris) can cause severe illness and spreads easily among sick patients in healthcare facilities. [4]
-
Often drug-resistant: Most strains resist at least one type of antifungal medicine, and some resist all three main classes. [4]
-
Lingers on skin and surfaces: Patients can carry it on their skin without symptoms and spread it to surfaces such as bedrails, where it can survive for a long time. [4]
-
New and rising: First described only in 2009, it now has a near-global distribution. [2] U.S. clinical cases rose nearly five-fold from 2019 to 2022. [5]
Key stats
-
300M+ people affected by fungal diseases each year worldwide [9]
-
19 fungi on WHO’s first fungal priority pathogens list (2022) [1]
-
4 classes of antifungal medicines available, with few candidates in the pipeline [1]
3. Few drugs: Only four main classes of antifungals
For decades, treatment has relied on just four classes of systemic antifungal drugs. [3] Developing drugs that harm fungi but not people is hard, because fungal and human cells are similar in their ribosomes, cytoskeletons and cell membranes. [11]
-
Azoles: Interfere with making membrane sterols (ergosterol). [11] Fluconazole is an example. [12]
-
Echinocandins: Block 1,3-β-D-glucan synthase, an enzyme that builds the cell wall. [3] Preferred for most C. auris infections. [4]
-
Polyenes: One of the four main classes of systemic antifungals. [3] Fungal ergosterol is a common antifungal target. [11]
-
Flucytosine: A pyrimidine analogue (5-flucytosine), the fourth main class. [3]
Antifungal drugs for systemic infections still tend to have more toxic side effects than antibiotics. [11] Antibiotics do not treat fungal infections and can even raise the risk of them. [7]
4. How antifungal resistance develops and spreads
All disease-causing fungi can become resistant when drugs put pressure on them. [3] Antifungal resistance is driven partly by widespread use of antifungals and similar chemicals in human, animal and plant health, and by environmental exposure. [9]

-
On farms. Heavy use of azole fungicides on crops has been linked to rising azole-resistant Aspergillus fumigatus. [1] These fungicides work the same way as medical antifungals. [2]
-
Through the air. Resistant A. fumigatus can spread passively over long distances in the air, so people can breathe in spores that are already resistant. [3, 2]
-
In the patient. Resistance can also evolve during antifungal therapy and cause treatment failure, in both molds and yeasts. [3]
-
In healthcare. C. auris spreads from patients’ skin to surfaces, equipment and other patients. [4]
5. Why antifungal treatment fails
Antifungal treatment fails for many reasons at once: the patient’s immune defenses, how the drug behaves in the body, and traits of the fungus such as its cell forms, tolerance and resistance. [3]
-
Target changes: Mutations change the drug’s target. Examples include changes to the lanosterol demethylase gene (azoles) or the β-glucan synthase gene (echinocandins). [3]
-
Efflux pumps: Pumps push azoles out of the cell. This is a main cause of azole resistance in Candida. [3, 12]
-
Built-in resistance: All Aspergillus species, Candida krusei and most C. auris isolates are naturally resistant to fluconazole, and many environmental molds, including Fusarium, resist azoles. [3]
-
Tolerance: Some drug-susceptible cells grow slowly even at drug levels that should stop them. [3]
-
Biofilm: Fungal cells in biofilms make a matrix that soaks up the drug, lowering the dose that reaches the cells. [3] See Biofilm 101 →
-
Few options: Only four antifungal classes exist, and most fungal pathogens lack rapid, sensitive diagnostics. [1] Fungal infections are often misdiagnosed, which can delay the right treatment. [7]
Sources
Pavaka Wound Care is developing a powered wound dressing designed to target biofilm and drug-resistant pathogens. Investigational device; not FDA cleared or approved.
Educational information, not medical advice. This page is general educational content. It does not describe the use or performance of any Pavaka product. If you have a wound or infection, talk with a qualified healthcare professional.
1. WHO. WHO releases first-ever list of health-threatening fungi (Fungal Priority Pathogens List). Oct 25, 2022. https://www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi
2. Fisher MC, Denning DW. The WHO fungal priority pathogens list as a game-changer. Nat Rev Microbiol. 2023;21(4):211–212. https://pmc.ncbi.nlm.nih.gov/articles/PMC9901396/
3. Fisher MC, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557–571. https://pmc.ncbi.nlm.nih.gov/articles/PMC8962932/
4. CDC. About C. auris. Reviewed Sept 28, 2026. https://www.cdc.gov/candida-auris/about/index.html
5. CDC. Antimicrobial Resistance Threats Reports (2026 update). Updated Oct 26, 2026. https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html
6. CDC. AR Threats Report 2026: Antimicrobial Resistance Threats (threat list). https://arpsp.cdc.gov/artr/antimicrobial-resistance-threats
7. CDC. About Fungal Diseases. Reviewed Oct 9, 2026. https://www.cdc.gov/fungal/about/index.html
8. CDC. Aspergillosis Basics. Reviewed Oct 1, 2026. https://www.cdc.gov/aspergillosis/about/index.html
9. WHO. New WHO report outlines critical steps to confront fungal disease and antifungal resistance. June 30, 2026. https://www.who.int/news/item/30-06-2026-new-who-report-outlines-critical-steps-to-confront-fungal-disease-and-antifungal-resistance
10. WHO. Antimicrobial resistance (fact sheet). https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
11. OpenStax. Microbiology, Section 5.3: Fungi. Rice University. https://openstax.org/books/microbiology/pages/5-3-fungi
12. CDC. About Antimicrobial Resistance. Updated Oct 25, 2026. https://www.cdc.gov/antimicrobial-resistance/about/index.html
13. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695–704. https://pubmed.ncbi.nlm.nih.gov/17934079/
